Johnson & Johnson (JNJ) : Rotella Capital Management added new position in Johnson & Johnson during the most recent quarter end. The investment management firm now holds 2,107 shares of Johnson & Johnson which is valued at $239,271 , the company said in a statement filed on May 13, 2016 with the SEC.Johnson & Johnson makes up approximately 9.69% of Rotella Capital Management’s portfolio.
Other Hedge Funds, Including , Doheny Asset Management Ca reduced its stake in JNJ by selling 500 shares or 1.08% in the most recent quarter. The Hedge Fund company now holds 45,889 shares of JNJ which is valued at $5.2 Million. Johnson & Johnson makes up approx 2.68% of Doheny Asset Management Ca’s portfolio.Dorsey Whitney Trust Co reduced its stake in JNJ by selling 157 shares or 0.15% in the most recent quarter. The Hedge Fund company now holds 103,510 shares of JNJ which is valued at $11.8 Million. Johnson & Johnson makes up approx 2.94% of Dorsey Whitney Trust Co’s portfolio. Cim Investment Mangement Inc added JNJ to its portfolio by purchasing 10,390 company shares during the most recent quarter which is valued at $1.2 Million. Johnson & Johnson makes up approx 0.51% of Cim Investment Mangement Inc’s portfolio.West Coast Financial reduced its stake in JNJ by selling 29 shares or 0.42% in the most recent quarter. The Hedge Fund company now holds 6,920 shares of JNJ which is valued at $780,161. Johnson & Johnson makes up approx 0.32% of West Coast Financial’s portfolio.
Johnson & Johnson opened for trading at $113.18 and hit $113.725 on the upside on Wednesday, eventually ending the session at $113.35, with a gain of 0.59% or 0.66 points. The heightened volatility saw the trading volume jump to 54,55,518 shares. Company has a market cap of $311,786 M.
On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.Company shares were Reiterated by RBC Capital Mkts on Apr 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $122 .Company shares were Reiterated by Piper Jaffray on Apr 20, 2016 to “Neutral”, Firm has raised the Price Target to $ 106 from a previous price target of $105 .
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.